Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Janux Therapeutics, Inc. (JANX : NSDQ)

• Company Description    Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif. Number of Employees: 81

• Price / Volume Information    Yesterday's Closing Price: $13.80 Daily Weekly Monthly 20 Day Moving Average: 2,182,684 shares Shares Outstanding: 60.15 (millions) Market Capitalization: $830.04 (millions) Beta: 2.88 52 Week High: $61.59 52 Week Low: $13.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.85% -15.71% 12 Week -46.62% -47.48% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10955 Vista Sorrento Parkway Suite 200 - San Diego,CA 92130 USA ph: 858-751-4493 fax: - investors@januxrx.com http://www.januxrx.com

• General Corporate Information    Officers David Campbell - President and Chief Executive Officer Ron Barrett - Chairperson of the Board of Directors Vickie Capps - Director Eric Dobmeier - Director Sheila Gujrathi - Director Peer Information Janux Therapeutics, Inc. (CORR.) Janux Therapeutics, Inc. (RSPI) Janux Therapeutics, Inc. (CGXP) Janux Therapeutics, Inc. (BGEN) Janux Therapeutics, Inc. (GTBP) Janux Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 47103J105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 60.15 Most Recent Split Date: (:1) Beta: 2.88 Market Capitalization: $830.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.85 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 23.53% vs. Previous Quarter: 29.09% Sales Growth vs. Year Ago Period: 2,177.90% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -10.18 06/30/25 - -11.48 ROA 12/31/25 - - 09/30/25 - -9.78 06/30/25 - -11.01 Current Ratio 12/31/25 - - 09/30/25 - 35.86 06/30/25 - 47.03 Quick Ratio 12/31/25 - - 09/30/25 - 35.86 06/30/25 - 47.03 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -1,018.95 06/30/25 - -24,064.01 Book Value 12/31/25 - - 09/30/25 - 16.25 06/30/25 - 16.74 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©